Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) on Friday, soared 8.85% from the previous trading day, before settling in for the closing price of $1.13. Within the past 52 weeks, ZNTL’s price has moved between $1.01 and $14.50.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of -3.49%. With a float of $54.00 million, this company’s outstanding shares have now reached $71.28 million.
Considering the fact that the conglomerate employs 166 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 99.03%, operating margin of -283.57%, and the pretax margin is -245.74%.
Zentalis Pharmaceuticals Inc (ZNTL) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Zentalis Pharmaceuticals Inc is 24.81%, while institutional ownership is 86.95%. The most recent insider transaction that took place on Feb 06 ’25, was worth 45,656. In this transaction Chief Medical Officer of this company bought 20,000 shares at a rate of $2.28, taking the stock ownership to the 36,629 shares. Before that another transaction happened on Feb 11 ’25, when Company’s Former Director proposed sale 687 for $2.00, making the entire transaction worth $1,374.
Zentalis Pharmaceuticals Inc (ZNTL) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -3.49% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 7.56% during the next five years compared to -12.89% drop over the previous five years of trading.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Trading Performance Indicators
Zentalis Pharmaceuticals Inc (ZNTL) is currently performing well based on its current performance indicators. A quick ratio of 7.32 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.31.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.33, a number that is poised to hit -0.64 in the next quarter and is forecasted to reach -2.28 in one year’s time.
Technical Analysis of Zentalis Pharmaceuticals Inc (ZNTL)
Compared to the last year’s volume of 1.67 million, its volume of 0.93 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 25.10%. Additionally, its Average True Range was 0.17.
During the past 100 days, Zentalis Pharmaceuticals Inc’s (ZNTL) raw stochastic average was set at 7.36%, which indicates a significant decrease from 21.89% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 112.22% in the past 14 days, which was higher than the 109.82% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.8471, while its 200-day Moving Average is $2.9755. Nevertheless, the first resistance level for the watch stands at $1.2900 in the near term. At $1.3500, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.4500. If the price goes on to break the first support level at $1.1300, it is likely to go to the next support level at $1.0300. Now, if the price goes above the second support level, the third support stands at $0.9700.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Key Stats
Market capitalization of the company is 88.33 million based on 71,812K outstanding shares. Right now, sales total 67,430 K and income totals -165,840 K. The company made 26,870 K in profit during its latest quarter, and -47,470 K in sales during its previous quarter.
